Welcome to our dedicated page for ZIMMER BIOMET HOLDINGS SEC filings (Ticker: ZBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ZIMMER BIOMET HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ZIMMER BIOMET HOLDINGS's regulatory disclosures and financial reporting.
ZBH shareholder Suketu Upadhyay submitted a Form 144 notice for a proposed sale of up to 7,668 shares of common stock through Fidelity Brokerage Services LLC. These shares have an aggregate market value of $712,050.48, when 193,462,482 common shares were outstanding, and are expected to be sold on or about July 16, 2026 on the NYSE.
The securities to be sold were acquired through restricted stock vesting as compensation on July 1, 2021 (2,543 shares), February 25, 2024 (2,483 shares), and March 6, 2024 (2,642 shares). Upadhyay also completed sales in the prior three months of 31,252 shares for $2,608,859.38 on May 12, 2026, 5,372 shares for $464,120.14 on May 19, 2026, and 4,560 shares for $410,696.40 on June 24, 2026.
Hilado Maria Teresa reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Maria Teresa Hilado received a grant of 389.498 Phantom Stock Units. These units track the value of Zimmer Biomet common stock on a 1-for-1 basis but are settled in cash, not shares.
The units were accrued under the company’s Deferred Compensation Plan for Non-Employee Directors. Following this award, Hilado now holds a total of 12,983.867 Phantom Stock Units. Settlement is scheduled in ten annual cash installments after her service as a director ends.
Zimmer Biomet Holdings director Devdatt Kurdikar received a grant of phantom stock units as part of board compensation. On the reported date, he acquired 180.323 phantom stock units under the company’s Deferred Compensation Plan for Non-Employee Directors, increasing his balance to 2,990.182 units.
Each phantom stock unit is linked 1-for-1 to a share of Zimmer Biomet common stock and is scheduled to be settled in company shares within sixty days after his service as a director ends.
HAGEMANN ROBERT reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings director Robert Hagemann received a grant of 317.369 Phantom Stock Units, equivalent on a 1-for-1 basis to shares of common stock. These units were accrued under the company’s Deferred Compensation Plan for Non-Employee Directors and are settled only in cash.
After this award, Hagemann holds a total of 33,269.443 Phantom Stock Units. The units will be paid out in five annual cash installments that begin within sixty days after the calendar year in which his service as a director ends, linking this compensation to his board tenure rather than near-term market trading.
HIGGINS ARTHUR J reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Arthur J. Higgins received a grant of 317.369 Phantom Stock Units under the company’s Deferred Compensation Plan for Non-Employee Directors. Each unit is linked 1-for-1 to a share of common stock but will be settled in cash, not stock.
After this award, Higgins holds a total of 37,674.691 Phantom Stock Units on a direct basis. These units are scheduled to be paid out in cash in ten annual installments, beginning within sixty days after the end of the calendar year in which his service as a director ends.
Kolli Sreelakshmi reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings, Inc. director Sreelakshmi Kolli received a grant of 180.323 phantom stock units as a compensation award under the company’s deferred compensation plan for non-employee directors. Following this grant, she holds a total of 6,842.604 phantom stock units, which will be settled in common stock within sixty days after her board service ends.
Farrell Michael J. reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Michael J. Farrell received a grant of 432.776 phantom stock units on June 30, 2026. These units are credited under the company’s Deferred Compensation Plan for Non-Employee Directors at a 1-for-1 rate with common stock and are to be settled in cash after his board service ends. Following this award, Farrell holds a total of 19,606.716 phantom stock units, reflecting routine, cash-settled director compensation rather than any open-market trading.
Shapiro Louis reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Louis Shapiro reported receiving a grant of phantom stock units as part of his non-employee director compensation. He was awarded 158.684 phantom stock units tied to company common stock on a 1-for-1 basis, bringing his total phantom stock holdings to 3,703.100 units. These units were accrued under the company’s Deferred Compensation Plan for Non-Employee Directors and will be settled in shares of Zimmer Biomet common stock within sixty days after he ceases serving as a director.
Zimmer Biomet Holdings, Inc. entered into two new unsecured revolving credit agreements to support general corporate purposes. The company established a five-year revolving facility of $1.5 billion maturing on June 26, 2031, with two optional one-year extensions, and an uncommitted incremental feature of up to $750 million.
It also put in place a separate 364-day revolving facility of $1.25 billion maturing on June 25, 2027. Both agreements bear floating interest based on adjusted Term SOFR or an alternate base rate plus a margin tied to the company’s senior unsecured long-term debt rating and require a consolidated indebtedness to consolidated EBITDA ratio not exceeding 4.5 to 1.0, with a step-up to 5.0 to 1.0 for qualified material acquisitions.
At the same time, Zimmer Biomet terminated its prior 2025 five-year and 364-day credit agreements, both of which had no principal outstanding. The company paid approximately $0.4 million of fees due under the prior five-year agreement using cash on hand, and existing letters of credit were transitioned to the new five-year facility.
ZBH submitted a Form 144 notice reporting proposed sales of Common Stock by a selling holder. The filing lists two recent sale transactions: 31,252 shares sold on 05/12/2026 for $2,608,859.38 and 5,373 shares sold on 05/19/2026 for $464,120.14.
The filing also records restricted stock vesting events of 2,091 shares on 07/01/2023 and 2,469 shares on 02/25/2024, and shows a broker/location entry referencing Fidelity Brokerage Services LLC with a date of 06/24/2026.